663941-72-8

Usage

Uses

Used in Pharmaceutical Synthesis:
4-Bromo-1-(2-chloroethyl)-1H-pyrazole is used as a reagent for the synthesis of tetrahydroquinoline derivatives, which are compounds with potential therapeutic applications. These derivatives have shown promise in the treatment of cancer, as well as chronic autoimmune and inflammatory diseases, making this intermediate a valuable component in the development of new medications.
Used in Cancer Treatment Research:
In the field of cancer treatment, 4-Bromo-1-(2-chloroethyl)-1H-pyrazole serves as a key intermediate in the synthesis of tetrahydroquinoline derivatives. These compounds have demonstrated potential in targeting and treating various types of cancer, offering new avenues for therapeutic intervention and improving patient outcomes.
Used in Chronic Autoimmune and Inflammatory Disease Management:
4-Bromo-1-(2-chloroethyl)-1H-pyrazole is also utilized in the synthesis of compounds that target chronic autoimmune and inflammatory diseases. The tetrahydroquinoline derivatives produced using this intermediate have shown potential in managing and treating these conditions, providing hope for more effective treatments in the future.

Upstream product

• 2075-45-8 4-bromo-1H-pyrazole 
• 107-04-0 1-Bromo-2-chloroethane 
• 107-06-2 1,2-dichloro-ethane 
• 107-07-3 2-chloro-ethanol 

Downstream Products

• 1301198-33-3 2-(4-bromo-1H-pyrazol-1-yl)-N-methyl-N-(phenylmethyl)ethanamine 
• 1226808-60-1 2-[2-(4-bromo-1H-pyrazol-1-yl)ethyl]-1H-isoindole-1,3(2H)-dione 
• 1301198-31-1 1-methylethyl [(2S,4R)-1-acetyl-2-methyl-6-(1-{2-[methyl(phenylmethyl)amino]ethyl}-1H-pyrazol-4-yl)-1 ,2,3,4-tetrahydro-4-quinolinyl]carbamate 
• 1183066-01-4 C₁₁H₁₁BrN₂S 
• 1426338-76-2 C₁₁H₁₁BrN₂Se 
• 1459733-93-7 C₁₂H₁₃BrCl₂N₂OPdTe 
• 1459733-96-0 4-bromo-1-[2-(4-methoxyphenyltellanyl)ethyl]-1H-pyrazole 
• 80308-80-1 4-bromo-1-vinylpyrazole 

Relevant academic research and scientific papers

Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors

The leucine-rich repeat kinase 2 (LRRK2) protein has been genetically and functionally linked to Parkinson's disease (PD), a disabling and progressive neurodegenerative disorder whose current therapies are limited in scope and efficacy. In this report, we

N-(HETEROARYL) QUINAZOLIN-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF

The present invention is directed to substituted certain N-(heteroaryl)quinazolin-2-amine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein J, R3, and R4, are as defined herein, which are potent inhib

Palladium(ii) complexes of pyrazolated thio/selenoethers: Syntheses, structures, single source precursors of Pd4Se and PdSe nano-particles and potential for catalyzing Suzuki-Miyaura coupling

The reactions of 4-bromo-1-(2-chloroethyl)-1H-pyrazole prepared from 4-bromopyrazole with the in situ generated PhSNa, PhSeNa, Na2S and Na2Se have resulted in thio/selenoether ligands L1-L4 respectively. The complexes [PdL1/L2Cl

Tetrahydroquinoline Derivatives And Their Pharmaceutical Use

Tetrahydroquinoline compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.

TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE

Tetrahydroquinoline compounds of Formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.

INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY

The invention relates to compounds of Formula (I) and their use for inhibiting protein tyrosine kinase activity In Formula (I), the group M is thieno[3,2,b]pyridinyl as shown, and the group D is a ring or ring system, and the groups Z, Ar, and G are as defined herein The invention relates particularly to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signalling, for example, the inhibition of VEGF receptor signalling and HGF receptor signalling The invention also provides compositions and methods for treating cell proliferative diseases and conditions, such as cancer, and for treating ophthalmic diseases, including age-related macular degeneration (AMD) and diabetic retinopathy (DR)